The use of Psychedelic drugs in the Palliative Care Setting
Dr Ross will be joining us to discuss this current study at St Vincent’s Hospital in Melbourne, which uses synthetic ‘psilocybin’ (a psychedelic compound found in ‘magic mushrooms’) in combination with psychotherapy, to treat depression and anxiety in people with advanced stage illnesses. She will also briefly discuss:
- The historical use of psilocybin in indigenous cultures.
- Why promising research in the 60’s (which indicated psychedelics could help alleviate fear of death in some cancer patients) ground to a halt very quickly.
- How psychedelic research in cancer related anxiety and depression resumed in 2000’s and why psilocybin + therapy could potentially ease psychological suffering in people with terminal illness.
We hope you can join us.
Dr Margaret Ross is the Chief Principal Investigator and Clinical Lead for Australia’s first psilocybin-assisted psychotherapy study treating depression and anxiety in the terminally ill. Her study is a world first investigating psilocybin assisted therapy for all palliative conditions.
Dr Ross is pioneering a new frontier in psychedelic medicine. She combines this ground-breaking trial with palliative medicine and clinical work in her role as Senior Clinical Psychologist and Senior Researcher at St. Vincent’s Hospital Melbourne.
“We see a lot of fear and despair in our terminally ill patients, so to be able to offer a novel trial treatment that has already shown such promise is excellent. It’s really a privilege to be able to conduct this research. This is one of the most exciting developments in psychiatric research in decades.”
This is a combined Second Hope & HOT Pink Sisters session.
To make a booking, please fill out the form below or call The Living Centre on 03 9820 2888. We will email you information on how to connect with Zoom once your booking has been confirmed.
If you are new to Think Pink, you will need to fill out a Client Registration Form before your booking can be confirmed.
1:00 pm - 2:00 pm
This program will take place via the online conferencing platform, Zoom.